Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy


Por: Ferrero V, Oset M, Masferrer J, Pardo E, Sorolla E, Largo S, Tormo V, Marcos M, Pardo J, Aymar N, Hortelano E, Flaquer A, Jorda E, Cordoba S, Corona J, Ferrer C, Frances A, Morillo V, Bouche A, Marin S, Cambray M, Ventura M, Perez H, Hernandez R, Martin J, Lorenzo L, Fuentes C, Zurita M, del Moral R, Munoz V, Gonzalez A, Enguix M, Martinez M, Ortiz M, Fernandez M, Cardenas E, Lozano A

Publicada: 1 dic 2019
Resumen:
Purpose Radiotherapy-induced dysfunction of the gastrointestinal tract is common in cancer patients and has a significant impact on their quality of life. In this study, we investigated the prevalence of breakthrough cancer pain (BTcP) in patients undergoing 3D pelvic radiotherapy and who had proctalgia. Methods This observational, multicenter, cross-sectional epidemiological study was performed in 13 Spanish hospitals. Data were obtained on the presence and characteristics of BTcP, demographics, common comorbidities, and treatments prescribed to the patients. Results The prevalence of BTcP in patients undergoing pelvic 3D external radiotherapy with proctalgia (N = 105) was 48.6% (95% CI 39.0-58.1%). BTcP was further characterized in 59 patients. The mean (+/- SD) intensity of the BTcP episodes was 7.45 +/- 1.47 in a visual analog scale. We found several statistically significant associations between the descriptive variables of BTcP with demographic and clinical variables associated with the tumor or the patient, such as an increased number of BTcP episodes per day depending on the presence or absence of diabetes (p = 0.001, Chi-square) or time to the onset of pain relief depending on the location of the tumor (p = 0.019, Chi-square). Fentanyl was the drug of choice in BTcP episodes for 95% of the patients. Conclusions This study demonstrated a high prevalence of BTcP prevalence in cancer patients undergoing pelvic 3D radiotherapy and with proctalgia. Although the variables determining the onset of BTcP are still unclear, our results could help in the design of future clinical studies addressing the treatment of BTcP in these patients.

Filiaciones:
Ferrero V:
 Hosp Univ St Joan DAlacant, Dept Radiat Oncol, Carretera Nacl 332 Alicante Valencia S-N, Alicante 03550, Spain

Oset M:
 Hosp Univ St Joan DAlacant, Dept Radiat Oncol, Carretera Nacl 332 Alicante Valencia S-N, Alicante 03550, Spain

Masferrer J:
 Hosp Univ Son Espases, Dept Radiat Oncol, Palma De Mallorca, Spain

Pardo E:
 Hosp Univ Araba, Dept Radiat Oncol, Vitoria, Spain

Sorolla E:
 Hosp Clin Univ Valencia, Dept Radiotherapy, Valencia, Spain

Largo S:
 Hosp Clin San Carlos, Dept Radiat Oncol, Madrid, Spain

Tormo V:
 Hosp Univ San Juan Alicante, Alicante, Spain

Marcos M:
 Hosp Univ San Juan Alicante, Alicante, Spain

Pardo J:
 Hosp Univ Son Espases, Palma De Mallorca, Spain

Aymar N:
 Hosp Univ Son Espases, Palma De Mallorca, Spain

Hortelano E:
 Hosp Univ Araba, Vitoria, Spain

Flaquer A:
 Hosp Univ Araba, Vitoria, Spain

Jorda E:
 Hosp Clin Univ Valencia, Valencia, Spain

Cordoba S:
 Hosp Clin San Carlos, Madrid, Spain

Corona J:
 Hosp Clin San Carlos, Madrid, Spain

Ferrer C:
 Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

Frances A:
 Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

Morillo V:
 Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

Bouche A:
 Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

Marin S:
 Inst Catala Oncol LHospitalet, Lhospitalet De Llobregat, Spain

Cambray M:
 Inst Catala Oncol LHospitalet, Lhospitalet De Llobregat, Spain

Ventura M:
 Inst Catala Oncol LHospitalet, Lhospitalet De Llobregat, Spain

Perez H:
 Inst Catala Oncol LHospitalet, Lhospitalet De Llobregat, Spain

Hernandez R:
 Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain

Martin J:
 Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain

Lorenzo L:
 Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain

Fuentes C:
 Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain

Zurita M:
 Complejo Hosp Reg Virgen de las Nieves, Granada, Spain

del Moral R:
 Complejo Hosp Reg Virgen de las Nieves, Granada, Spain

Munoz V:
 Hosp Meixoeiro, Vigo, Spain

Gonzalez A:
 Hosp Meixoeiro, Vigo, Spain

Enguix M:
 Hosp Meixoeiro, Vigo, Spain

Martinez M:
 Hosp Meixoeiro, Vigo, Spain

Ortiz M:
 Hosp Virgen del Rocio, Seville, Spain

Fernandez M:
 Hosp Virgen del Rocio, Seville, Spain

Cardenas E:
 Hosp Clin Univ Virgen de la Arrixaca, Murcia, Spain

Lozano A:
 Hosp Clin Univ Virgen de la Arrixaca, Murcia, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 21 Número: 12
Páginas: 1707-1711
WOS Id: 000495304300011
ID de PubMed: 30949931

MÉTRICAS